EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia

Manon Queudeville, Anthony S Stein, Franco Locatelli, Martin Ebinger, Rupert Handgretinger, Nicola Gökbuget, Lia Gore, Yi Zeng iD, Priya Gokani, Gerhard Zugmaier, Hagop M Kantarjian

Cancer · 2023

DOI: 10.1002/cncr.34667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Manon Queudeville und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Pediatrics, Hematology and Oncology, Children's University Hospital Tübingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antibodies, Bispecific, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A lower baseline bone marrow blast percentage (bBMB%) is associated with better outcomes in patients with B‐cell acute lymphoblastic leukemia (B‐ALL) receiving blinatumomab. The objective of this analysis was to investigate the association between bBMB% and treatment outcomes in relapsed/refractory (R/R) B‐ALL.

Methods

Data from five trials of blinatumomab for R/R B‐ALL were pooled for analyses. Patients were placed in one of three groups: group 1, ≥50% bBMBs; group 2, ≥25% to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPrecursor Cell Lymphoblastic Leukemia-LymphomaAntibodies, BispecificPrecursor B-Cell Lymphoblastic Leukemia-LymphomaLymphoma, B-CellAdultHumansChildRecurrenceAcute Disease

Stichwörter der Autor:innen

acute lymphoblastic leukemiabispecific antibodiesblinatumomableukemia burdentreatment efficacy

Substanzen

Antineoplastic AgentsblinatumomabAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of General Pediatrics, Hematology and Oncology, Children's University Hospital Tübingen, Tübingen, Germany.
  • Gehr Family Center for Leukemia Research, City of Hope, Duarte, California, USA.
  • Department of Paediatric Haematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy.
  • Department of Medicine, University Hospital, Goethe University, Frankfurt, Germany.
  • Section of Pediatric Hematology/Oncology/Bone Marrow Transplant-Cellular Therapeutics, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Oncology TA, Amgen Inc., Thousand Oaks, California, USA.

ORCID-Profile: Yi Zeng

Zitieren

APA

Queudeville, M., Stein, A. S., Locatelli, F., Ebinger, M., Handgretinger, R., Gökbuget, N., Gore, L., Zeng, Y., Gokani, P., Zugmaier, G., & Kantarjian, H. M. (2023). Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia. Cancer. https://doi.org/10.1002/cncr.34667

Vancouver

Queudeville M, Stein AS, Locatelli F, Ebinger M, Handgretinger R, Gökbuget N, et al. Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia. Cancer. 2023. doi:10.1002/cncr.34667

BibTeX
@article{Queudeville2023,
  author = {Queudeville, Manon and Stein, Anthony S and Locatelli, Franco and Ebinger, Martin and Handgretinger, Rupert and Gökbuget, Nicola and Gore, Lia and Zeng, Yi and Gokani, Priya and Zugmaier, Gerhard and Kantarjian, Hagop M},
  title = {Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34667}
}
Kostenlos starten →